Trial Profile
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Bortezomib (Primary) ; Crisantaspase (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Fludarabine (Primary) ; Ifosfamide (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Prednisolone (Primary) ; Prednisolone (Primary) ; Prednisone (Primary) ; Tioguanine (Primary) ; Vincristine (Primary) ; Vindesine (Primary)
- Indications Acute biphenotypic leukaemia; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms AIEOP-BFM ALL 2017
- 12 Dec 2023 Results (n=728) assessing toxicity profile of B-cell acute lymphoblastic leukemia patients with high-risk characteristics pending final outcome data, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results collecting samples from this study analyzing Immune Profiling , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 16 Dec 2021 This trial has been restarted in Germany and ongoing in Austria, Italy, Slovakia and Czech Republic according to European Clinical Trials Database record